Phase 1 results of ABBV-400, a c-Met-targeting ADC, in advanced G/GEJA
Автор: VJOncology
Загружено: 2024-10-31
Просмотров: 271
Описание:
John Strickler, MD, Duke Cancer Institute, Durham, NC, discusses findings from a Phase I study (NCT05029882) of ABBV-400, a c-Met–targeting antibody-drug conjugate (ADC) for advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA). ABBV-400 had some promising antitumor activity and a manageable safety profile, and common treatment-emergent adverse events (TEAEs) included anemia, nausea, and thrombocytopenia. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
